Invest Now
Samco securities limited
Samco Star Rating Ads

Aurobindo Pharma Ltd

₹ 1,567.25 +5.80 (0.37%)

Updated on 15-09-2024 6:56 AM

Stock Rating

Pros 4

 

Cons 7

Price Performance

  • Day's Low
  • ₹1,555
  • Day's High
  • ₹1,592
₹ 1,567.25
  • 52-w low
  • ₹834.65
  • 52-w high
  • ₹1,592
1,567.25
  • Day's open
    ₹1,565
  • Previous close
    ₹1,561.45
  • VWAP
    ₹1,570.13
  • Lower price band
    ₹1,410.55
  • Upper price band
    ₹1,723.95

Today's Market Action

The last traded share price of Aurobindo Pharma Ltd was 1,567.25 up by 0.37% on the NSE. Its last traded stock price on BSE was 1,563.20 up by 0.19%. The total volume of shares on NSE and BSE combined was 1,254,584 shares. Its total combined turnover was Rs 196.98 crores.

Medium and Long Term Market Action

Aurobindo Pharma Ltd hit a 52-week high of 1,592 on 15-09-2024 and a 52-week low of 834.65 on 01-11-2023. The stock price of Aurobindo Pharma Ltd is up by 5% over the last one month. It is up by 74.92% over the last one year. Don't forget to check the full stock price history in the table below.

Fundamentals

  • Market Cap (Cr): 91831

  • Book Value (₹):

  • Stock P/E:

  • Revenue (Cr):

  • Total Debt (Cr):

  • Face Value (₹):

  • Roce (%):

  • ROE (%):

  • Earnings (Cr):

  • Promoter’s Holdings (%):

  • EPS (₹):

  • Debt to Equity:

  • Dividend Yield (%):

  • Cash (Cr):

Mutual fund holdings and trends

FUND NAME Quantity Monthly Change (Qty)

Shareholding Pattern

Similar Stocks

Company Price Market Cap (Cr) P/E

About

Data not available.

FAQ's

What is Share Price of Aurobindo Pharma Ltd?

What is the Market Cap of Aurobindo Pharma Ltd?

What is PE Ratio of Aurobindo Pharma Ltd?

What is PB Ratio of Aurobindo Pharma Ltd?

What is the CAGR of Aurobindo Pharma Ltd?

How to Buy Aurobindo Pharma Ltd Share?

(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Cash Flow)

Standalone Financial Performace In Graph(Cash Flow)

Pros

  • Momentum Strength
    The stock is currently exhibiting strong momentum, & is showing consistent strong relative strength.
  • Above Average Sustainable RoE
    The company generates a sustainable return on equity greater than the expected cost of capital which implies that the underlying business can create and compound value over a period time due to it's ability to generate above average return on capital.
  • High Pricing Power
    The business enjoys a relatively high pricing power and is able to withstand competitive pressure which works as a great moat for equity shareholders of the company.
  • Above Average Growth Rate
    The company is estimated to grow its earnings at a reasonable rate over the next few years which will drive shareholder value creation

Cons

  • Low Return on Capital Employed
    The company is unable to generate sufficient return on capital employed which impairs it's ability to generate high return for shareholders after accounting for taxes, interest and other non-equity stakeholders.
  • Poor Cash Flow Conversion
    The business has very poor cash conversion ratio of only 39.32% of operating earnings getting converted into operating cash flow. This implies that increase in profits has not translated into higher cash flows for the business and incrementally higher investments in working capital which works negatively for shareholders.
  • Highly Cyclical Industry
    The company operates an extremely cyclical business with unpredictable earnings and cash flows. This shall result in very high stock price volatility and returns which would negatively impact shareholder returns.
  • Capital Intensive Business
    The company operates an extremely capital intensive business with a low Asset turnover ratio of 1.52. A low asset turnover ratio negatively impacts RoE and reduces shareholder returns. Also due to the capital intensive nature of business, growth of the business would need to be funded either via increasing borrowings or diluting shareholders, both of which shall negatively impact shareholder value and returns.
  • Poor Working Capital Cycle
    The company has a very poor working capital cycle of 191 days which requires very high investments in working capital. This reduces free cash flow generation for the business and negatively impacts shareholder value and returns.
  • High Promoter Pledge
    The company has a relatively high promoter pledge to the extent of 21% of the total company's shareholding which can have a significantly negative impact on stock.
  • Negative Margin of Safety
    The relative margin of safety of investing in the company is low due to a recent sharp run up in stock prices.

Valuation Analysis

Margin of safety
(15/09/2024)
Stock Valuation
Yellow line
84
78.38%
78.38% People are bullish about Aurobindo Pharma Ltd
21.62%
21.62 % People are bearish about Aurobindo Pharma Ltd

What is your opinion about this Stock?

Historical Data

Samco Star Rating Ads

Aurobindo Pharma Ltd

₹ 1,567.25 +5.80 (0.37%)

Brokerage & Taxes at Samco

Brokerage & Taxes at Other traditional broker

Potential Brokerage Savings with Samco ₹ 49.62()

Top Gainers (NIFTY 50)

Stock Name Change %

    Top Losers (NIFTY 50)

    Stock Name Change %

      ×

      Filing Complaints on SCORES

      Easy & quick Easy & quick

      1. Register on SCORES portal

      2. Mandatory details for filling complaints on SCORES

      Name | PAN | Address | Mobile | Number | E-mail ID

      3. Benefits

      Effective Communication

      Speedy redressal of the grievances

      Website Icon